Inhibrx Biosciences Inc 뉴스 - INBX | 주식 나스닥 | ADVFN

다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Inhibrx Biosciences Inc (INBX)
Inhibrx Biosciences Inc (INBX) 뉴스

Inhibrx Biosciences Inc (INBX)

12.49

-0.07

(-0.56%)

종가: 25 2월 6:00AM

12.49

0.01

( 0.08% )

시간외 거래: 6:03AM

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the...

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance PR Newswire SAN DIEGO, Jan. 13, 2025 SAN...

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results PR Newswire SAN DIEGO, Nov. 14, 2024 SAN...

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation PR Newswire SAN...

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PR...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Monksdream

Monksdream 4 월 전

Monksdream

Monksdream 5 월 전

Monksdream

Monksdream 6 월 전

Monksdream

Monksdream 11 월 전

TrendTrade2016

TrendTrade2016 2 년 전

heres the dolla...boom!!

TrendTrade2016

TrendTrade2016 2 년 전

INBX DOLLA RUMMER IN PROCESS

TrendTrade2016

TrendTrade2016 2 년 전

INBX...PRE MARKET VOL

Jaydixson1

Jaydixson1 2 년 전

Seems to be dropping

make it happen

make it happen 2 년 전

Numbers do not make sense. They need to raise so much to keep the Phases going. So much debt and money burn with worse quarters and barley any revs. Not bashing it's just what it is. 1,000's of percent's negative on profit. Revenue $0.18 Book Value -$0.12. Also imo this volume isn't sustainable 9 times normal as of now

Profitability
Profit Margin 0.00%
Operating Margin -1,448.76%

Management Effectiveness
Return on Assets -37.98%
Return on Equity -562.25%

Income Statement
Revenue 7.03M
Revenue Per Share 0.18
Quarterly Revenue Growth (yoy) -25.50%
Gross Profit -64.21M
EBITDA -100.6M
Net Income Avi to Common -110.75M
Diluted EPS -2.44

Balance Sheet
Total Debt 175.7M
Book Value Per Share -0.13

Cash Flow Statement
Operating Cash Flow -90.16M
Levered Free Cash Flow -46.31M

Inhibrx Biosciences

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관